Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast Cancer
Publication in refereed journal


Times Cited
Web of Science86WOS source URL (as at 13/07/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractEstrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers in the management of breast carcinoma. They are not always analyzed in distant metastatic and locally recurrent breast cancers. We compared immunohistochemical expression in a series of primary breast carcinomas with their distant metastases (n = 72) and local recurrences (n = 45) and analyzed the impact of any changes on survival. Discordance rates between primary and metastatic and between primary and locally recurrent lesions, respectively, were 18% (13/72) and 13% (6/45) for ER, 42% (30/72) and 33% (15/45) for PR, and 7% (5/72) and 2% (1/45) for c-ERBB2. There was statistically significant discordance between primary and metastatic PR status (P = .017; kappa = 0.201). Among locally recurrent tumors, 15 (33%) of 45 revealed discordance for PR (P = .006; kappa = 0.366). We observed a trend for shorter survival among women with ER metastatic and locally recurrent tumors regardless of the primary tumor ER status. Our findings suggest a benefit for routine evaluation of ER, PR, and c-ERBB2 status in distant metastatic and locally recurrent breast cancer for therapeutic and prognostic purposes.
All Author(s) ListIdirisinghe PKA, Thike AA, Cheok PY, Tse GMK, Lui PCW, Fook-Chong S, Wong NS, Tan PH
Journal nameAmerican Journal of Clinical Pathology
Year2010
Month3
Day1
Volume Number133
Issue Number3
PublisherOxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
Pages416 - 429
ISSN1943-7722
LanguagesEnglish-United Kingdom
KeywordsBreast cancer; c-ERBB2; Discordance; Hormone receptors; Local recurrence; Metastases
Web of Science Subject CategoriesPathology; PATHOLOGY

Last updated on 2020-14-07 at 00:09